Key Dates

Related Announcements

RFA-HL-21-001 - Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01 - Clinical Trials Required)
 

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that NHLBI has posted a set of responses to Frequently Asked Questions (FAQs) for RFA-HL-21-001 "Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01 - Clinical Trials Required)". The FAQs are available on the NHLBI website at the following link: https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/all-funding-opportunity-announcements/RFA-HL-21-001.

Applicants are strongly encouraged to review the FAQs, which may be updated at any time without additional notice, prior to submitting their application.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Lora Reineck, M.D., M.S.
Division of Lung Diseases
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0222
Email: [email protected]

Lawton Cooper, M.D., M.P.H.
Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0419
Email: [email protected]

Cheryl Boyce, Ph.D.
Center for Translation Research and Implementation Science
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-496-1051
Email: [email protected]

Andrei Kindzelski, M.D., Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0050
Email: [email protected]

Peer Review Contact(s)

Director, Office of Scientific Review
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0270
Email: [email protected]

Financial/Grants Management Contact(s)

Taryn Cobb
National Heart, Lung, and Blood Institute (NHLBI
Telephone: 301-435-0222
Email: [email protected]